Table 3.
Classification of participants based on types of COVID-19 vaccines and number of doses.
| Vaccine | Participants n (%) |
Dose n (%) |
|
|---|---|---|---|
| One | Two | ||
| Pfizer-BioNTech 1 | 5310 (52.8) | 2948 (56) | 2362 (44) |
| AstraZeneca 2 | 2087 (20.7) | 1200 (57) | 887 (43) |
| Sinopharm 3 | 1433 (14.2) | 511 (36) | 922 (64) |
| Sputnik V 4 | 587 (5.8) | 299 (51) | 288 (49) |
| SinoVac 5 | 468 (4.6) | 306 (65) | 162 (35) |
| Moderna 6 | 121 (1.2) | 35 (29) | 86 (71) |
| Johnson & Johnson 7 | 58 (0.6) | 57 (98) | 1 (2) |
| Total | 10,064 | 5356 (53) | 4708 (47) |
Developer(s): 1 Pfizer Inc., New York City, NY, USA and BioNTech SE, Mainz, Germany; 2 AstraZeneca plc, Cambridge, UK; 3 China National Pharmaceutical Group Corporation, Beijing, China; 4 Gamaleya Research Institute of Epidemiology and Microbiology, Moscow, Russia; 5 Sinovac Biotech, Beijing, China; 6 Moderna Inc., Cambridge, MA, USA; 7 Janssen Vaccines, Leiden, The Netherlands.